Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01451632 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
A Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, sponsored by Merrimack Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 4
- Study locations
NCT01451632 is a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer that has completed, run by Merrimack Pharmaceuticals. The registered enrollment target is 48 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT01451632, a Phase 1 study of Non-Small Cell Lung Cancer and Colorectal Cancer, has completed, sponsored by Merrimack Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG Irinotecan
- DRUG MM-121
Study Locations (4)
California
- - San Francisco
Massachusetts
- - Boston
North Carolina
- - Chapel Hill
Utah
- - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01451632
The ClinicalTrials.gov registry entry for NCT01451632 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cetuximab is the first listed.
NCT01451632 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01451632 about?
NCT01451632 is a clinical study titled "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers". The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
What is the current status of trial NCT01451632?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-10. Estimated completion is 2014-06.
What conditions does trial NCT01451632 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Squamous Cell Head and Neck Cancer, Other Tumors With EGFR Dependence.
What interventions are being tested in trial NCT01451632?
The interventions under investigation include: Cetuximab (DRUG), Irinotecan (DRUG), MM-121 (DRUG).
Who is sponsoring clinical trial NCT01451632?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01451632 being conducted?
This trial has 4 study locations across California, Massachusetts, North Carolina, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.